Journal of Experimental & Clinical Cancer Research · 2018 · 27 citations · 29 references
MedicineCancer BiologyOncologyMolecular OncologyOncogenesTumor ProgressionCancer Molecular PathologyCancer ProgressionColorectal CancerMalignant NeoplasmsOncogenic Signaling PathwaysRas Family OncogenesColorectal Cancer PrognosisColorectal Carcinogenesis PathophysiologyPrognostic Molecular StratificationRas Pathway ActivationRas Signaling PathwayRegulation By Small GtpasesTissue Microarray AnalysisTumor Invasion Assessment
BACKGROUND: Colorectal cancer (CRC) is a commonly diagnosed digestive malignancy worldwide. Ras-related protein 1A (RAP1A) is a member of the Ras superfamily of small GTPases and has been recently identified as a novel oncoprotein in several human malignancies. However, its specific role in CRC remains unclear. METHOD: In this study, we firstly analyzed its expression and clinical significance in a retrospective cohort of 144 CRC patients. Then, cellular assays in vitro and in vivo were performed to clarify its biological role in CRC cells. Finally, microarray analysis was utilized to investigate the molecular mechanisms regulated by RAP1A in CRC progression. RESULTS: Firstly, RAP1A expression was abnormally higher in CRC tissues as compared with adjacent normal tissues, and significantly correlated tumor invasion. High RAP1A expression was an independent unfavourable prognostic factor for CRC patients. Combining RAP1A expression and preoperative CEA level contributed to a more accurate prognostic stratification in CRC patients. Secondly, knockdown of RAP1A dramatically inhibited the growth of CRC cells, while it was opposite for RAP1A overexpression. Finally, the microarray analysis revealed RAP1A promoted CRC growth partly through phosphatase and tensin homolog (PTEN)/forkhead box O3(FOXO3)/cyclin D1(CCND1) signaling pathway. FOXO3 overexpression could partly mimic the inhibitory effect of RAP1A knockdown in CRC growth. Moreover, FOXO3 overexpression inhibited CCND1 expression, but had no impact on RAP1A and PTEN expression. CONCLUSION: RAP1A promotes CRC development partly through PTEN/FOXO3 /CCND1 signaling pathway. It has a great potential to be an effective clinical biomarker and therapeutic target for CRC patients.
29
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Global cancer statistics, 2012
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text
Colorectal cancer statistics, 2017
Rebecca L. Siegel, Kimberly D. Miller, Stacey A. Fedewa et al. · CA A Cancer Journal for Clinicians · 2017 · 3.9K citations · Full text
Herb Brody · Nature · 2015 · 486 citations · Full text
Activation of Rap1 Promotes Prostate Cancer Metastasis
Candice L. Bailey, Patrick Kelly, Patrick J. Casey · Cancer Research · 2009 · 155 citations · Full text